Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical powerhouse headquartered in New York, New York, United States. As one of the world's largest pharmaceutical companies, Pfizer maintains leadership positions across vaccines, oncology, internal medicine, and gene therapy, serving patients in more than 125 countries with a workforce of approximately 83,000 employees. The company generated approximately $68 billion in revenue during fiscal year 2025, cementing its position among the Fortune 60 and maintaining a brand heat score of 920 out of 1000 as the industry leader.

Core Business

Pfizer operates as a fully integrated biopharmaceutical company spanning research, development, manufacturing, and commercialization. The company's vaccine portfolio represents a cornerstone of its business, anchored by Comirnaty, the globally significant COVID-19 vaccine, alongside the Prevnar series of pneumonia vaccines and Abrysvo, an innovative respiratory syncytial virus vaccine that achieved remarkable growth with sales of $2.5 billion and an 85.5% year-over-year increase. The company maintains the world's largest vaccine production capacity across eight dedicated vaccine manufacturing bases.

In oncology, Pfizer has established itself as a major player through targeted therapies and immunooncology treatments including checkpoint inhibitors, generating approximately $17 billion in revenue with a robust 12.5% growth rate. The internal medicine segment provides foundational stability through products like Eliquis, a leading anticoagulant with $4.5 billion in annual sales, as well as rare disease treatments and anti-infective medications. The company continues expanding into gene therapy and novel technologies, including mRNA platforms and hemophilia treatments, positioning itself for future growth across 100+ active development projects in its pipeline.

Global Presence

Pfizer's manufacturing and operational footprint spans 125 countries across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East. The company operates 58 global manufacturing facilities, including 18 active pharmaceutical ingredient plants, 32 finished dose facilities, and 8 dedicated vaccine production sites strategically distributed across North America, Europe, and Asia. With 25 research and development centers located in global innovation hubs and over 12,000 R&D personnel representing 14.5% of the workforce, Pfizer maintains substantial operational scale across all major markets.

Revenue distribution reflects a balanced global portfolio: the North American market contributes approximately 50% of total sales, European markets account for 25%, Asia-Pacific represents a high-growth segment at 20% with 8.5% growth rate, and remaining emerging markets contribute 5%. The company's China operations generate approximately $4 billion in annual revenue, representing a strategic priority for future expansion.

Key Strengths

Pfizer's competitive advantages stem from its unparalleled research and development capabilities, with annual R&D investment exceeding $11.4 billion representing 16.8% of revenue, supporting a pipeline of 100+ projects and maintaining over 15,000 active patents. The company produces an average of 5-8 new drugs or vaccines annually, demonstrating sustained innovation output. Its global manufacturing network adheres to the strictest quality standards with full regulatory compliance across all major markets, while its comprehensive product portfolio spanning vaccines, oncology, and internal medicine provides diversification that supports financial resilience. The company's strong cash generation with $16 billion in operating cash flow and net income of approximately $13 billion in FY2025 enables continued investment in innovation and strategic acquisitions.